Metalyse 40mg Injection is a clinically established pharmaceutical preparation containing TENECTEPLASE as its primary active ingredient. It falls under the Cardiology therapeutic class and is widely prescribed for the management of associated medical conditions. The medicine exerts its action through a well-defined pharmacological mechanism, targeting specific receptors, enzymes, or biological pathways to produce the desired clinical effect. Metalyse 40mg Injection is available in Injection form and is administered as directed by a qualified healthcare professional. The pharmacokinetic profile of TENECTEPLASE — including absorption, distribution, metabolism, and excretion — has been well-characterized through clinical studies, enabling predictable and reliable dosing in most patient populations. This medicine is classified under the Anticoagulants general category and the Cardiology speciality domain, reflecting its targeted use in managing conditions within this therapeutic area. Patients should note that Metalyse 40mg Injection is a prescription-only medicine and must be used only under the supervision of a licensed physician. Dosage and treatment duration must be individualized based on the patient's clinical condition, age, weight, organ function, and concurrent medications.

• Primary Indication: Used as a clot-dissolving (thrombolytic) agent in the management of acute ST-elevation myocardial infarction (STEMI). • Combination Therapy: May be used as part of a multi-drug regimen to achieve synergistic therapeutic effects and improve overall treatment outcomes. • Monotherapy: Can be prescribed as a standalone agent where single-drug therapy is appropriate based on disease severity and patient profile. • Maintenance Therapy: Used for long-term disease control and prevention of relapse or progression in chronic cardiology conditions following initial stabilization. • Prophylaxis: Prescribed preventively in high-risk patients to reduce the likelihood of disease onset, recurrence, or complications. • Post-Operative / Intensive Care Use: In select clinical scenarios, may be administered in hospital settings for post-operative recovery or specialized therapeutic interventions.

Metalyse 40mg Injection containing TENECTEPLASE exerts its therapeutic effects through a well-defined pharmacological mechanism relevant to cardiology conditions. It is a fibrin-specific thrombolytic that converts plasminogen to plasmin, breaking down the fibrin clot causing the coronary blockage. The pharmacokinetic properties of TENECTEPLASE — including protein binding, volume of distribution, metabolism, and renal or biliary excretion — contribute to a reliable therapeutic profile. Dose adjustments may be required in patients with renal impairment, hepatic dysfunction, or in elderly populations. Regular therapeutic monitoring is recommended to ensure optimal drug levels, evaluate treatment response, and detect early signs of toxicity or therapeutic failure.

• Always inform your doctor about every medicine you are currently taking before starting Metalyse 40mg Injection — prescription drugs, OTC medications, vitamins, minerals, and herbal products. • Anticoagulants/Antiplatelets: Concurrent use with other anticoagulant or antiplatelet agents may increase the risk of bleeding — monitor closely. • NSAIDs and Analgesics: May increase risk of gastrointestinal bleeding and renal impairment when used together. • Nephrotoxic Agents: Avoid concurrent use with medicines known to cause kidney damage unless supervised by a specialist. • Carry a complete updated medicine list whenever visiting any healthcare provider, emergency facility, or dentist to ensure safe prescribing and prevent harmful drug interactions.

Metalyse 40mg Injection is a prescription-only medicine (Schedule H / H1 or equivalent) and must not be purchased or used without a valid prescription from a licensed medical practitioner. Storage: Store below 25°C away from direct sunlight and moisture. Refrigerate (2–8°C) if indicated on pack. Keep out of reach of children. Disposal: Do not flush unused medicines or dispose in household waste; return unused or expired medicines to a licensed pharmacy. Pharmacovigilance: Report any unexpected, severe, or serious adverse effects to your doctor immediately and to the national pharmacovigilance authority (e.g., CDSCO in India) through the online ADR reporting system.